DK216189D0 - Rekombinant antistof - Google Patents

Rekombinant antistof

Info

Publication number
DK216189D0
DK216189D0 DK216189A DK216189A DK216189D0 DK 216189 D0 DK216189 D0 DK 216189D0 DK 216189 A DK216189 A DK 216189A DK 216189 A DK216189 A DK 216189A DK 216189 D0 DK216189 D0 DK 216189D0
Authority
DK
Denmark
Prior art keywords
pct
sec
recombinant antibody
date
surface pocket
Prior art date
Application number
DK216189A
Other languages
English (en)
Other versions
DK216189A (da
DK172630B1 (da
Inventor
Mark William Bodmer
John Robert Adair
Nigel Richard Whittle
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of DK216189D0 publication Critical patent/DK216189D0/da
Publication of DK216189A publication Critical patent/DK216189A/da
Application granted granted Critical
Publication of DK172630B1 publication Critical patent/DK172630B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK198902161A 1987-09-04 1989-05-03 Modificeret antistofmolekyle eller derivat heraf og fremgangsmåde til fremstilling af det modificerede antistofmolekyle DK172630B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878720833A GB8720833D0 (en) 1987-09-04 1987-09-04 Recombinant dna product
GB8720833 1987-09-04
PCT/GB1988/000730 WO1989001974A1 (en) 1987-09-04 1988-09-05 Recombinant antibody
GB8800730 1988-09-05

Publications (3)

Publication Number Publication Date
DK216189D0 true DK216189D0 (da) 1989-05-03
DK216189A DK216189A (da) 1989-05-03
DK172630B1 DK172630B1 (da) 1999-03-22

Family

ID=10623277

Family Applications (3)

Application Number Title Priority Date Filing Date
DK216089A DK216089A (da) 1987-09-04 1989-05-03 Rekombinant antistof og fremgangsmaade til dets fremstilling
DK215889A DK215889D0 (da) 1987-09-04 1989-05-03 Rekombinant antistof
DK198902161A DK172630B1 (da) 1987-09-04 1989-05-03 Modificeret antistofmolekyle eller derivat heraf og fremgangsmåde til fremstilling af det modificerede antistofmolekyle

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK216089A DK216089A (da) 1987-09-04 1989-05-03 Rekombinant antistof og fremgangsmaade til dets fremstilling
DK215889A DK215889D0 (da) 1987-09-04 1989-05-03 Rekombinant antistof

Country Status (11)

Country Link
US (1) US5219996A (da)
EP (3) EP0329755A1 (da)
JP (3) JPH02501191A (da)
AT (2) ATE102254T1 (da)
AU (3) AU617367B2 (da)
CA (2) CA1337640C (da)
DE (2) DE3888172T2 (da)
DK (3) DK216089A (da)
FI (3) FI892135A0 (da)
GB (1) GB8720833D0 (da)
WO (3) WO1989001974A1 (da)

Families Citing this family (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625856B2 (en) * 1987-07-15 1992-07-16 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
WO1990004410A1 (en) * 1988-10-19 1990-05-03 The Dow Chemical Company A novel family of high affinity, modified antibodies for cancer treatment
US5215889A (en) * 1988-11-18 1993-06-01 The Regents Of The University Of California Catalytic and reactive polypeptides and methods for their preparation and use
US5162218A (en) * 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5714149A (en) * 1989-02-10 1998-02-03 Celltech Therapeutics Limited Crosslinked antibodies and processes for their preparation
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
GB8903021D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
GB8916400D0 (en) * 1989-07-18 1989-09-06 Dynal As Modified igg3
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
US6495137B1 (en) 1990-04-19 2002-12-17 The Dow Chemical Company Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
US5976531A (en) * 1990-04-19 1999-11-02 The Dow Chemical Company Composite antibodies of human subgroup IV light chain capable of binding to tag-72
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB2276169A (en) * 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU654563B2 (en) * 1991-07-24 1994-11-10 Imperial Chemical Industries Plc Proteins
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993012231A1 (en) * 1991-12-13 1993-06-24 Dow Chemical (Australia) Limited Composite antibodies of human subgroup iv light chain capable of binding to tag-72
CA2103887C (en) * 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
RU94045919A (ru) 1992-02-06 1996-11-10 Шеринг Корпорейшн (US) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US6365124B1 (en) * 1998-02-06 2002-04-02 Biocrystal, Ltd. Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
JP3439195B2 (ja) 2000-02-17 2003-08-25 浜松ホトニクス株式会社 抗原の定量的検出方法
EP2341074A1 (en) * 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
ATE353913T1 (de) 2000-04-21 2007-03-15 Fuso Pharmaceutical Ind Neue collectine
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
PT1642910E (pt) * 2000-12-05 2012-03-22 Alexion Pharma Inc Anticorpos concebidos de modo racional
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002062850A2 (en) * 2001-02-02 2002-08-15 Millennium Pharmaceuticals, Inc. Hybrid antibodies and uses thereof
DK1366067T3 (da) * 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7569673B2 (en) 2002-06-28 2009-08-04 The United States Of America As Represented By The Department Of Health And Human Services Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
AU2003287345A1 (en) 2002-10-31 2004-06-07 Genentech, Inc. Methods and compositions for increasing antibody production
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
WO2005000901A2 (en) * 2003-05-09 2005-01-06 Duke University Cd20-specific antibodies and methods of employing same
AU2004252170B2 (en) * 2003-06-27 2011-01-27 Biogen Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20050100543A1 (en) 2003-07-01 2005-05-12 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
JP4818917B2 (ja) * 2003-08-08 2011-11-16 イミューノメディクス、インコーポレイテッド 腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
GB0325836D0 (en) * 2003-11-05 2003-12-10 Celltech R&D Ltd Biological products
WO2005051422A1 (en) * 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
GB0329825D0 (en) * 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
JP2008501638A (ja) 2004-04-23 2008-01-24 ドイツ連邦共和国 ＩＣＯＳ陽性細胞のｉｎｖｉｖｏ枯渇によるＴ細胞介在病態の治療方法
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
PL1791565T3 (pl) * 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
JP2008518936A (ja) * 2004-10-29 2008-06-05 メディミューン，インコーポレーテッド Ｒｓｖ感染症および関連状態を予防および治療する方法
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
ES2665422T3 (es) 2005-03-03 2018-04-25 Immunomedics Inc. Anticuerpos L243 humanizados
WO2006104989A2 (en) * 2005-03-29 2006-10-05 Verenium Corporation Altered antibody fc regions and uses thereof
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP2586798A3 (en) 2005-07-25 2013-08-07 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
WO2007031734A1 (en) * 2005-09-14 2007-03-22 Ucb Pharma S.A. Comb polymers
BRPI0619595B8 (pt) 2005-12-09 2022-12-13 Ucb Pharma Sa anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado
WO2007087673A1 (en) 2006-02-01 2007-08-09 Arana Therapeutics Limited Domain antibody construct
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
CA2699837C (en) 2006-12-01 2017-06-13 Seattle Genetics, Inc. Variant target binding agents and uses thereof
MX2009010120A (es) 2007-03-22 2009-10-19 Ucb Pharma Sa Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2008261042A1 (en) * 2007-06-08 2008-12-11 Dow Global Technologies Inc. Expression of soluble antibody fragment by truncation of CH1 domain
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
GB0717337D0 (en) 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
EP2209808B1 (en) 2007-10-19 2014-01-15 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
AU2008329466B2 (en) 2007-11-27 2015-04-09 The University Of British Columbia 14-3-3 antagonists for the prevention and treatment of arthritis
NZ586357A (en) 2007-11-30 2012-10-26 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2009092011A1 (en) * 2008-01-18 2009-07-23 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
US8709715B2 (en) 2008-03-26 2014-04-29 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
SG10201505038TA (en) * 2009-02-17 2015-07-30 Ucb Biopharma Sprl Antibody molecules having specificity for human ox40
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
AU2010236256C1 (en) 2009-04-16 2015-10-22 Abbvie Biotherapeutics Inc. Anti-TNF-alpha antibodies and their uses
JP5785941B2 (ja) 2009-06-17 2015-09-30 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｖｅｇｆ抗体とその使用
US20120283415A1 (en) 2009-09-10 2012-11-08 Ucb Pharma S.A. Multivalent Antibodies
GB0916630D0 (en) 2009-09-22 2009-11-04 Secr Defence Antibody
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
NZ599971A (en) 2009-10-16 2014-12-24 Servier Lab Monoclonal antibodies to progastrin and their uses
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
GB0922434D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
WO2011059762A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
ES2594893T3 (es) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
WO2011117653A1 (en) 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
MA34907B1 (fr) 2011-01-14 2014-02-01 Ucb Pharma Sa Molécules d'anticorps se liant à il-17a et il-17f
CN103958544B (zh) 2011-09-16 2018-04-24 Ucb医药有限公司 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013078455A2 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Proteomic identification of antibodies
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
SG11201506025RA (en) * 2013-02-08 2015-08-28 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
BR112015023084A2 (pt) 2013-03-15 2017-11-21 Abbvie Biotechnology Ltd anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
EP2970489A2 (en) 2013-03-15 2016-01-20 AbbVie Biotechnology Ltd Anti-cd25 antibodies and their uses
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
KR102325240B1 (ko) 2014-01-20 2021-11-11 유씨비 바이오파마 에스알엘 고체 형태의 약학 조성물의 재형성 방법
WO2015123265A1 (en) 2014-02-11 2015-08-20 Seattle Genetics, Inc. Selective reduction of proteins
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP2944962A1 (en) 2014-05-14 2015-11-18 UCB Biopharma SPRL Method for determining antibody specificity
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CA2957354A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2016054114A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 修飾された重鎖定常領域を含む抗体
US10100129B2 (en) 2014-11-21 2018-10-16 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
DK3237432T3 (da) 2014-12-22 2023-11-20 UCB Biopharma SRL Proteinfremstilling
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
EA201792388A1 (ru) 2015-04-30 2018-06-29 Президент Энд Феллоуз Оф Гарвард Колледж Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
US10316097B2 (en) 2015-05-27 2019-06-11 Ucb Biopharma Sprl Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody
AU2016289755C1 (en) 2015-07-06 2021-08-19 UCB Biopharma SRL Tau-binding antibodies
EP4137158A1 (en) * 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017030156A1 (ja) 2015-08-19 2017-02-23 国立研究開発法人理化学研究所 非天然アミノ酸導入抗体
EA201890613A1 (ru) 2015-09-21 2018-10-31 Аптево Рисёрч Энд Девелопмент Ллс Полипептиды, связывающие cd3
KR20180067676A (ko) 2015-10-27 2018-06-20 유씨비 바이오파마 에스피알엘 항-il-17a/f 항체를 사용한 치료 방법
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
GB201602414D0 (en) 2016-02-10 2016-03-23 Nascient Ltd Biological materials and uses thereof
PT3219727T (pt) 2016-03-17 2021-01-21 Tillotts Pharma Ag Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
SI3219726T1 (sl) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
JP7184746B2 (ja) 2016-03-17 2022-12-06 ヌマブ イノヴェイション アーゲー 抗ＴＮＦα抗体およびそれらの機能的断片
WO2017158101A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
IL261261B2 (en) 2016-03-17 2024-04-01 Numab Therapeutics AG Antibodies against TNF-ALPHA and their functional fragments
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
EP3589320A4 (en) 2017-02-28 2020-12-23 Seagen Inc. CYSTEIN-MUTED ANTIBODIES FOR CONJUGATION
WO2019004943A1 (en) 2017-06-30 2019-01-03 Aslan Pharmaceuticals Pte Ltd METHOD OF TREATMENT USING ANTIBODY DIRECTED AGAINST IL-13R
AU2018379320B2 (en) 2017-12-05 2023-06-15 Progastrine Et Cancers S.À R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
SG11202008271QA (en) 2018-02-27 2020-09-29 Ecs Progastrin Sa Progastrin as a biomarker for immunotherapy
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
BR112021007092A2 (pt) 2018-10-16 2021-08-03 UCB Biopharma SRL método para o tratamento de miastenia grave
WO2020197502A1 (en) 2019-03-26 2020-10-01 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
KR20220088847A (ko) 2019-09-04 2022-06-28 주식회사 와이바이오로직스 항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
IL303294A (en) 2020-12-07 2023-07-01 UCB Biopharma SRL Antibodies against interleukin-22
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
KR20230156727A (ko) 2021-03-03 2023-11-14 피에르 파브르 메디카먼트 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
KR20240037188A (ko) 2021-04-30 2024-03-21 피에르 파브르 메디카먼트 신규의 안정한 항-vista 항체
AU2022268545A1 (en) 2021-05-03 2023-11-02 UCB Biopharma SRL Antibodies
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334102D0 (en) * 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
EP0329755A1 (en) 1989-08-30
AU2301388A (en) 1989-03-31
DK215889A (da) 1989-05-03
FI892136A0 (fi) 1989-05-03
WO1989001782A1 (en) 1989-03-09
DK216089D0 (da) 1989-05-03
JPH02501800A (ja) 1990-06-21
GB8720833D0 (en) 1987-10-14
WO1989001974A1 (en) 1989-03-09
US5219996A (en) 1993-06-15
FI892137A (fi) 1989-05-03
AU2301688A (en) 1989-03-31
EP0348442A1 (en) 1990-01-03
ATE84973T1 (de) 1993-02-15
DK216189A (da) 1989-05-03
WO1989001783A2 (en) 1989-03-09
DK172630B1 (da) 1999-03-22
AU2421888A (en) 1989-03-31
FI892135A (fi) 1989-05-03
JPH02501191A (ja) 1990-04-26
DE3877955D1 (de) 1993-03-11
JP2675380B2 (ja) 1997-11-12
CA1337640C (en) 1995-11-28
FI892136A (fi) 1989-05-03
FI892135A0 (fi) 1989-05-03
WO1989001783A3 (en) 1989-04-20
JP2761012B2 (ja) 1998-06-04
AU614303B2 (en) 1991-08-29
ATE102254T1 (de) 1994-03-15
DE3888172D1 (de) 1994-04-07
DK215889D0 (da) 1989-05-03
DE3888172T2 (de) 1994-06-30
AU611202B2 (en) 1991-06-06
EP0348442B1 (en) 1993-01-27
FI892137A0 (fi) 1989-05-03
EP0347433B1 (en) 1994-03-02
AU617367B2 (en) 1991-11-28
DE3877955T2 (de) 1993-07-22
JPH02501190A (ja) 1990-04-26
CA1337641C (en) 1995-11-28
DK216089A (da) 1989-05-03
EP0347433A1 (en) 1989-12-27

Similar Documents

Publication Publication Date Title
DE3888172D1 (de) Rekombinant-antikörper.
ES2068907T3 (es) Secuencias de nucleotidos que codifican una proteina con actividad ureasica.
SE8204810D0 (sv) Recombinant dna molecule, transformed microorganism and process for producing protein a
HU903425D0 (en) Process for the production of medicines closely related to the calcytonine gene for treating potential disorder
ES2058538T3 (es) Compuestos de proteina a purificados y procedimiento para su preparacion.
DE69006395D1 (de) Nährstoff-Zusammensetzungen für die Ergänzung an Aminosäuren bei Säugetieren.
PT92148A (pt) Processo para a preparacao de pomada contendo colesterol para o tratamento topico de dermatoses
NO895028L (no) Ny chimerisk transformerende vekstfaktor-beta.
DK0383599T3 (da) Protein-anticancermiddel
ATE113986T1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
ES2173879T3 (es) Procedimiento para la preparacion de conjugados a base de un participe especifico en la fijacion y de una proteina que contiene hidratos de carbono
DE69014300T2 (de) Radioaktive markierung von proteinen.
DK549886D0 (da) Enzymproces
DE3872888T2 (da)
BR8305272A (pt) Composto de 1,2,3,4-tetra-hidro-1-aminometil-4-fenil-isoquinolina e processo de preparacao
HU9302658D0 (en) Process for completing traditional pair compasses of 2 mm graphite point to that with element suitable for holding thin (0.8, 0.5, 0.3 mm) graphite point
HUT49151A (en) Process for production of biotinilated proteins
ES262943U (es) Util escritor, ambivalente.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired